Drug Trial Radar · NCT00705939
Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jun 2008
Primary completion
May 2012
Study completion Aug 2013
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 27, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in the cells of the monocyte-macrophage system. This is an extension trial to Study NCT00376168 and NCT00712348.
Conditions
- Gaucher Disease
Interventions
Taliglucerase alfaDrug
Intravenous infusion every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Spleen VolumeTime frame: Spleen Volume at Baseline and Months 12, 24, and 36
Locations
11 sites in 8 countries. Site status is shown where the registry gives one.
Department of Human Genetics, Emory University School of Medicine
Decatur, Georgia
Neurogenetics, NYU at Rivergate
New York, New York
Bone Marrow Transplant Service, The Royal Melbourne Hospital
Parkville, Victoria, Australia
Mount Sinai Hospital
Toronto, Ontario, Canada
Pontificia Universidad Catolica de Chile
Santiago, Chile
Rambam Medical Center
Haifa, Israel
Shaare Zedek Medical Center
Jerusalem, Israel
Morningside Medi-Clinic
Morningside, South Africa
Hospital Universitario Miguel Servet
Zaragoza, Spain
Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust
Cambridge, United Kingdom
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.